Tag: GlobeNewswire

BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) — Merlin, Inc. (Nasdaq: MRLN), an aerospace and defense technology company building the operating system of record for autonomous flight, today announced its management is scheduled to participate in three investor conferences in the fourth quarter of 2026.        

Upcoming investor conferences:

• Maxim Growth Summit 2026, October 12^th-14^th, New York City
• ROTH Capital Partners 15^th Annual ROTH Technology Conference, November 17th-18^th, New York City
• Northland Growth Conference, December 16^th (Virtual)

For additional information or to schedule attendance or meetings at any of these events, investors should contact their representative at the respective host company.

About Merlin

Merlin is an aerospace and defense technology company building the operating system of record for autonomous flight. Through a first-principles approach, the company is redefining what’s possible across aviation, aerospace, and defense with the goal of delivering full-stack autonomy for any aircraft, military or civilian, from takeoff to touchdown. The Merlin Pilot system powers a growing range of aircraft and mission profiles, proven through hundreds of autonomous flights from test facilities across the globe. With $100M+ total in IDIQ contract ceiling value under its C-130J autonomy program with USSOCOM, Merlin is advancing American leadership in autonomous aviation by helping to solve national security challenges through safe, reliable autonomy. To learn more, visit www.merlinlabs.com or follow us on X @merlinaero.

Contacts

Investor Relations: investor.relations@merlinlabs.com
Media: media@merlinlabs.com

Multi-year renewal extends Adeia’s long-standing relationship with the nation’s leading video provider

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Adeia Inc. (Nasdaq: ADEA), the technology company pioneering foundational innovations that shape how the world computes, connects and experiences entertainment, today announced that it has entered into a multi-year renewal of its intellectual property (IP) license agreement with Charter Communications, Inc., through its Spectrum brand. The agreement renews Spectrum’s license to Adeia’s media IP portfolio across its pay-TV and other video services and also includes coverage for Spectrum’s broadband and mobility businesses.

This agreement marks the latest in a series of renewals with Spectrum, the nation’s leading video provider, whose relationship with Adeia and its predecessor companies spans more than two decades.

“This key renewal with Spectrum underscores the enduring strength and relevance of our media IP portfolio in the pay-TV market,” said Dr. Mark Kokes, chief revenue officer of Adeia. “The agreement also extends coverage to Spectrum’s broadband and mobility businesses, reflecting the growing relevance of our innovations as video, broadband and mobile services increasingly converge. We are proud to continue our long-standing relationship with Spectrum and to support the entertainment experiences it delivers to millions of customers across the country.”

Adeia’s media IP portfolio has been developed through decades of research and development and is broadly licensed across the global media, entertainment and connectivity ecosystems. The company’s innovations are embedded in billions of devices worldwide, enabling advanced functionality across pay-TV, streaming, connected TV, broadband, and wireless platforms.

About Adeia

Adeia Inc. (Nasdaq: ADEA) develops foundational innovations that shape how the world computes, connects and experiences entertainment. Its inventions span a broad range of semiconductor and media technologies, including 3D interconnect (hybrid bonding) and advanced thermal management for AI datacenters, as well as content discovery, personalization, and streaming. These inventions are licensed to leaders across the chip design and manufacturing, consumer electronics, automotive, digital entertainment, and e-commerce industries. Adeia’s innovations enable more powerful and efficient products, and more immersive, personalized experiences across billions of devices worldwide. Learn more at www.adeia.com.

Adeia Investor Relations
Chris Chaney
IR@adeia.com

Adeia Media Relations
Anna Enerio
marketing@adeia.com

KING OF PRUSSIA, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) — Universal Health Services, Inc. (NYSE: UHS) announced today that it will report results for its third quarter ended September 30, 2026, after the market closes on Monday, October 26, 2026. There will be a conference call for investors and analysts on Tuesday, October 27, 2026, at 9:30 a.m. Eastern Time.

A live webcast and audio archive of the call may be accessed through the investor relations section of the company’s website at ir.uhs.com. To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

About Universal Health Services
Headquartered in King of Prussia, PA, Universal Health Services, Inc. (NYSE: UHS) is one of the nation’s largest and most respected providers of hospital and healthcare services. Since our founding in 1979, UHS has grown steadily into a premier Fortune 500® corporation perennially recognized by multiple esteemed national rating entities. Through its subsidiaries, UHS employs more than 102,000 employees and operates 30 inpatient acute care facilities, more than 380 inpatient behavioral health facilities, approximately 170 outpatient and other facilities, nationwide virtual behavioral health services, an insurance offering, a physician network and various related services with physical locations in 40 states, Washington, D.C., Puerto Rico, Ireland and the United Kingdom. www.uhs.com  

Investor Contact:
Darren Lehrich
610-382-3310
Darren.Lehrich@uhsinc.com

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts have been accepted for presentation at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting^® 2026, being held November 5 – 9, 2026 in Denver, CO. The abstracts released today can be found on the AASLD website at https://www.aasld.org/the-liver-meeting.

Details on the abstracts are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection

Abstract #: 4139
Title: Immune-modulatory effects of pevifoscorvir sodium in HBeAg-positive patients with chronic hepatitis B infection
Presenter: Professor Lung-Yi Loey Mak, MBBS(HK), MD(HK), MRCP(UK), PDipID (HK), FHKCP, FHKAM (Medicine), FRCP (Glasg), FRCP (Edin), FRCP, Clinical Assistant Professor at The University of Hong Kong
Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT
Session: Hepatitis B (“4001-4193”); Poster of Distinction

Abstract #: 4142
Title: Pevifoscorvir Sodium Reduces HBsAg Levels to < 3000 IU/mL in HBeAg Positive Subjects with Chronic HBV Infection Following Long-Term On-Study Treatment
Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT
Session: Hepatitis B (“4001-4193”)

Abstract #: 4158
Title: Pevifoscorvir Sodium (CAM-E) is Superior to Nucleos(t)ide Analogs in Suppressing Hepatitis B Virus Double-stranded Linear DNA In Vitro
Presenter: Andreas Jekle, PhD
Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT
Session: Hepatitis B (“4001-4193”)

ALG-170675: Potential best-in-class antisense oligonucleotide (ASO) for chronic hepatitis B virus (HBV) infection

Abstract #: 4156
Title: The potentially best-in-class HBV ASO ALG-170675 demonstrates a favourable preclinical profile: efficacy in an AAV-HBV mouse model, pharmacokinetics and safety in mouse and monkey
Presenter: Jin Hong, PhD
Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT
Session: Hepatitis B (“4001-4193”)

Preclinical

Abstract #: 3224
Title: Potent Inhibition of Hepatitis Delta Virus Replication by the Antisense Oligonucleotide ALG-215007
Presenter: Kellan Passow, PhD
Date/Time: November 7, 2026 at 1:00pm – 2:00pm MT
Session: Hepatitis – Other Infections (“3195-3246”)

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ plans to advance its pipeline and develop best-in-class therapies for the treatment of liver and viral diseases. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com

CHICAGO, Oct. 05, 2026 (GLOBE NEWSWIRE) — Sprout Social, Inc. (“Sprout Social”, the “Company”, “Sprout”) (NASDAQ: SPT), a leading AI-powered Social Intelligence Platform, today announced that it will report its financial results for the third quarter ending September 30, 2026 after market close on Tuesday, November 3, 2026.

The Company’s third quarter 2026 financial results and business highlights will be discussed on a conference call via webcast scheduled at 3:30 p.m. Central Time (4:30 p.m. Eastern Time) on Tuesday, November 3, 2026. Online registration for the webcast can be found at https://events.q4inc.com/attendee/. The live audio webcast and investor presentation can be accessed from Sprout Social’s Investors website at http://investors.sproutsocial.com.

While not all of the information that the Company posts to the Sprout Social Investors website or to social media profiles is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media, and others interested in Sprout Social to review the information that it shares at the Investors link located at the bottom of the page on www.sproutsocial.com and to regularly follow our social media profiles. Users may automatically receive email alerts and other information about Sprout Social when enrolling an email address by visiting “Email Alerts” in the “Shareholder Services” section of Sprout Social’s Investor website at https://investors.sproutsocial.com/.

Social Media Profiles:

www.X.com/SproutSocial
www.X.com/SproutSocialIR
www.facebook.com/SproutSocialInc
www.linkedin.com/company/sprout-social-inc-/
www.instagram.com/sproutsocial

Following completion of the events, a webcast replay will also be available at http://investors.sproutsocial.com for 12 months.

About Sprout Social

Sprout Social is a leading AI-powered Social Intelligence Platform, built on the belief that All Business is Social℠. Powered by Trellis, Sprout’s proprietary AI agent, the platform is designed to transform real-time social media signals into actionable insights that drive business forward. Consistently recognized as a top software by G2, Sprout enables brands to deliver smarter, faster business impact through a suite of solutions including comprehensive publishing and engagement, customer care, influencer marketing, advocacy and predictive media intelligence. Sprout’s software operates across all major social networks and digital platforms. For more information about Sprout Social (NASDAQ: SPT), visit sproutsocial.com.

Availability of Information on Sprout Social’s Website and Social Media Profiles

Investors and others should note that Sprout Social routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Sprout Social Investors website. We also intend to use the social media profiles listed below as a means of disclosing information about us to our customers, investors and the public.

Contact

Media:
Kaitlyn Gronek
Email: pr@sproutsocial.com
Phone: (773) 904-9674

Investors:
Lexi Johnson
Twitter: @SproutSocialIR
Email: investors@sproutsocial.com
Phone: (312) 528-9166

Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer

FREMONT, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR) a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the appointment of Bob Ragusa to its board of directors. Mr. Ragusa brings more than two decades of leadership across genomics, diagnostics and biotech. Most recently, he served as CEO of GRAIL, the pioneering multi-cancer early detection company, and previously as chief operations officer of Illumina.

“I am thrilled to join the Alamar team at such an exciting moment for the company,” said Bob Ragusa. “Throughout my career, I have seen how the right technology can change what is possible in medicine. I believe the future of disease detection lies in multi-marker testing using proteins, which reflect what is happening in the body in real time. Alamar’s NULISA platform has the sensitivity to measure many of these proteins at once from a small sample, and I look forward to helping the team bring that capability to researchers and, ultimately, to patients.”

Alamar also announced two additions to its leadership team. John Brottem has joined as general counsel, bringing legal leadership experience across medical technology and technology companies. He has served as general counsel of Outset Medical, Inc. and held various senior legal positions at Omnicell, Inc.

Amelia Merrill has joined as Chief People Officer, bringing extensive experience leading people and talent functions at high-growth healthcare and technology companies. She has served as Senior Vice President, People at Guardant Health, Senior Vice President, People Strategy at RMS, and Vice President, People Operations at Outset Medical. She has also held senior roles at VeriSign, webMethods and Juniper Networks.

“I am delighted to welcome Bob to our board of directors,” said Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences. “Bob helped build Illumina into the global standard for genomics and led GRAIL as it brought multi-cancer early detection to patients. Few people understand as well as he does what it takes to scale a platform company in our industry. His perspective will be invaluable as we advance our mission to enable the earliest detection of disease. I am also pleased to welcome John and Amelia to our leadership team. I look forward to their contributions as we scale the organization to support our next phase of growth.”

About Alamar Biosciences 
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO® HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com. 

Forward Looking Statements 
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar Biosciences’ ability to help enable the earliest detection of disease. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property, and the other risks described in Alamar Biosciences’ filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q filed with the SEC on August 11, 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. 

Media Contact: 
Media@alamarbio.com 

Investor Contact: 
Investors@alamarbio.com 

Net Asset Value Expected to be $12.25 to $12.75 Per Share

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — Neostellar Capital Corp. (“Neostellar Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: NSLR) today provided a preliminary update on its investment portfolio for the third quarter ended September 30, 2026.

“During the third quarter, we remained encouraged by the growth prospects of our core portfolio, supported by expanding AI adoption, increasing demand for compute and continued innovation in digital health,” said Mark Klein, Chairman and Chief Executive Officer of Neostellar Capital.

“While the IPO market showed early signs of reopening in Q3, the recovery has been slower than anticipated amid macroeconomic and geopolitical uncertainty. We remain confident in the strength of our portfolio companies and their ability to pursue liquidity opportunities, including IPOs, when timing and market conditions support long-term value creation.”

“As always, our shareholders’ best interests guide our decisions. Consistent with our prior practice, our shelf registration filing preserves the flexibility to raise capital when doing so would be accretive to shareholders. We will exercise that flexibility with discipline and a continued focus on building long-term shareholder value,” Mr. Klein concluded.

Preliminary Net Asset Value

As previously reported, the Company’s net assets totaled approximately $355.9 million, or $13.44 per share, as of June 30, 2026, compared to approximately $231.8 million, or $9.23 per share, as of September 30, 2025. As of September 30, 2026, the Company’s net asset value is estimated to be between $12.25 and $12.75 per share.

Investment Portfolio Update

As of September 30, 2026, the Company held positions in 34 portfolio companies – 30 privately held and 4 publicly held.

During the three months ended September 30, 2026, the Company made the following investment:

Portfolio Company	Investment	Transaction Date	Amount(1)
Shogun Enterprises, Inc. (d/b/a Hearth)(2)	Common Shares	7/10/2026	<$0.1 million

___________________
   (1) Amount invested does not include capitalized costs or prepaid expenses, if applicable.
   (2) On July 10, 2026, the Company exercised 86,076 warrants and received 86,076 Common Shares of Shogun Enterprises, Inc. (d/b/a Hearth).

During the three months ended September 30, 2026, the Company exited and/or received proceeds from the following investments:

Portfolio Company	Transaction Date	Quantity/ Initial Capital	Average Net Share Price(1)	Net Proceeds	Realized Gain/(Loss)
GrabAGun Digital Holdings Inc. – Common Shares(2)	Various	143,655	$3.12	$0.4 million	$0.3 million
Aventine Property Group, Inc.	7/8/2026	312,500	$0.10	<$0.1 million	$(2.5 million)
CW Opportunity 2 LP	8/21/2026	3.8%	N/A	$2.0 million	$1.4 million(3)
Learneo, Inc. (f/k/a Course Hero, Inc.)	9/21/2026	2,421,168	$3.88	$9.4 million	$(5.6 million)
CTN Holdings, Inc. (d/b/a Catona Climate, f/k/a Aspiration Partners, Inc.)(4)	9/25/2026	565,182	N/A	$-	$(1.3 million)

__________________
   (1) The average net share price is the net share price realized after deducting all commissions and fees on the sale(s), if applicable.
   (2) As of September 30, 2026, the Company holds 308,964 common shares of GrabAGun Digital Holdings, Inc.
   (3) CW Opportunity 2 LP is an SPV for which the Class A Interest is solely invested in the Class A Common Shares of CoreWeave, Inc. Realized gain is calculated based on the current reporting by the SPV and may be subject to change or adjustment due to the impact of performance fees.
   (4) On September 25, 2026, the Company abandoned its investment in CTN Holdings, Inc. (d/b/a Catona Climate, f/k/a Aspiration Partners, Inc.).

The Company’s liquid assets were approximately $42.2 million as of September 30, 2026, consisting of cash and securities of publicly traded portfolio companies not subject to certain restrictions at quarter-end.

As of September 30, 2026, there were 26,473,222 shares of the Company’s common stock outstanding.

Magnetar 6.50% Redeemable Promissory Note due 2029

On July 17, 2026, the Company received gross proceeds of $20.0 million pursuant to a redeemable promissory note issued to a Magnetar-affiliated entity. The redeemable promissory note bears interest at 6.50% per annum, payable semiannually in cash, and matures on July 16, 2029, unless earlier repaid through the issuance of shares of the Company’s common stock upon the completion of a transaction or series of transactions that result in at least $230.0 million of gross proceeds to the Company. In such event, the outstanding principal and accrued interest would be satisfied through the issuance of shares of the Company’s common stock at the price per share of common stock sold by the Company in the latest of such transactions in which the Company raised at least $5.0 million in aggregate net proceeds from sales to purchasers that were not affiliates of the Company. The Company believes the financing enhances liquidity and financial flexibility as the Company continues to execute its investment strategy.

Note Repurchase Program

On October 29, 2025, the Company’s Board of Directors approved an extension of the discretionary note repurchase program (the “Note Repurchase Program”) which allows the Company to repurchase up to an additional $40.0 million or the remaining aggregate principal amount, of its 6.00% Notes due 2026 (the “6.00% Notes”) through open market purchases, including block purchases, in such manner as will comply with the provisions of the Investment Company Act of 1940, as amended, and the Securities Exchange Act of 1934, as amended.

During the quarter ended September 30, 2026, we repurchased an additional 1,984 of the 6.00% Notes under the Note Repurchase Program. As of September 30, 2026, we had repurchased 1,568,791 of the 6.00% Notes under the Note Repurchase Program. The aggregate principal dollar amount of 6.00% Notes that may yet be repurchased by the Company under the Note Repurchase Program is approximately $35.8 million, or the remaining aggregate principal amount, of its 6.00% Notes.

Preliminary Estimates and Guidance

The preliminary financial estimates provided herein are unaudited and have been prepared by, and are the responsibility of, the management of the Company. Neither our independent registered public accounting firm, nor any other independent accountants, have audited, reviewed, compiled, or performed any procedures with respect to the preliminary financial data included herein. Actual results may differ materially.

The Company expects to announce its third quarter ended September 30, 2026 results in November 2026.

Forward-Looking Statements

Statements included herein, including statements regarding Neostellar Capital’s beliefs, expectations, intentions, or strategies for the future, may constitute “forward-looking statements”. Neostellar Capital cautions you that forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those projected or implied in these statements. All forward-looking statements involve a number of risks and uncertainties, including the impact of any market volatility that may be detrimental to our business, our portfolio companies, our industry, and the global economy; risks relating to our externally managed structure and our relationship with Neostellar Advisors LLC (the “Adviser”), Magnetar Holdings LLC and their respective affiliates, including actual and potential conflicts of interest; our ability to retain key personnel and execute our investment strategy; and other risks and uncertainties that could cause actual results to differ materially from the plans, intentions, and expectations reflected in or suggested by the forward-looking statements. Risk factors, cautionary statements, and other conditions which could cause Neostellar Capital’s actual results to differ from management’s current expectations are contained in Neostellar Capital’s filings with the Securities and Exchange Commission. Neostellar Capital undertakes no obligation to update any forward-looking statement to reflect events or circumstances that may arise after the date of this press release.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Neostellar Capital. The information contained herein is for informational purposes only and is not intended to be a substitute for financial, legal, or tax advice.

About Neostellar Capital Corp.

Neostellar Capital Corp. (Nasdaq: NSLR), formerly SuRo Capital Corp. (Nasdaq: SSSS), has been a publicly traded investment company focused on investing in private, venture-backed businesses for over 15 years. In simple terms, Neostellar invests in companies that are not yet listed on a public stock exchange. By owning shares of Neostellar, investors can gain exposure to a portfolio of VC-backed companies through a publicly traded stock. Neostellar is externally managed by Neostellar Advisors LLC, a joint venture owned by certain Neostellar Advisors employees and Magnetar Holdings LLC.   Together, the platform combines experience in private company investing with institutional investment management capabilities. Neostellar Capital Corp. is headquartered in New York, NY and has an office in San Francisco, CA. Connect with the Company on X, LinkedIn, and at neostellar.vc.

About Neostellar Advisors LLC

Neostellar Advisors LLC is registered with the SEC as an investment adviser under the Investment Advisers Act of 1940, and serves as the external investment adviser to Neostellar Capital Corp. Formed in 2026, Neostellar Advisors LLC is a joint venture between certain executives of Neostellar Capital Corp. and Magnetar Holdings LLC, combining Neostellar’s publicly traded venture investing experience with Magnetar’s institutional sourcing and underwriting.

Contact
Neostellar Capital Corp.
(212) 931-6331
IR@neostellaradvisors.com

Media Contact
Deborah Kostroun
Neostellar.pr@zitopartners.com

MONTREAL, Oct. 05, 2026 (GLOBE NEWSWIRE) — NanoXplore Inc. (“NanoXplore” or the “Company”) (TSX: GRA and OTCQX: NNXPF) today announced that its wholly owned subsidiary, VoltaXplore Inc. (“VoltaXplore”), has created an Advisory Board to provide strategic guidance as it advances its battery manufacturing strategy, and has appointed Mr. Jonathan Blanshay, founder and Chief Executive Officer of Galvion Inc., as its first member. Galvion Inc. is a global defence company that designs, develops and delivers advanced head systems, intelligent power and data management solutions, and integrated soldier systems. The company has a long history of defence innovation, developing and fielding technologies that address evolving operational requirements.

The Company’s President and Chief Executive Officer, Mr. Rocco Marinaccio, stated: “Jonathan built Galvion into a global defence company. He understands how defence customers evaluate and adopt new technology, and he has deep relationships across defence organizations in Canada, the United States and allied nations. Galvion’s power and data business also gives him direct insight into what soldiers need from batteries. We are pleased to welcome Jonathan as the inaugural member of VoltaXplore’s Advisory Board.

Commenting on his appointment, Blanshay said: “Reliable, resilient power has become fundamental to the modern warfighter, and demand will only increase as soldiers become increasingly reliant on powered technologies. But capability is only part of the equation. Defence customers also need secure, dependable supply chains and technologies that can be produced at scale. Building an advanced cylindrical-cell manufacturing capability here in Canada has real strategic value, both for Canada and for our allied partners. I’m pleased to join VoltaXplore’s Advisory Board and bring Galvion’s experience in soldier power and defence markets to help translate that capability into solutions that meet real operational requirements.”

About NanoXplore Inc.

NanoXplore is a graphene company and the largest manufacturer and supplier of high-volume graphene powder for use in multiple end markets with up to 5,000 tonnes of annual production capacity. The Corporation also provides standard and custom graphene-enhanced plastic and composite products to customers in the recreational vehicle, transportation, packaging, electronics, and other industrial sectors, and manufactures silicon-graphene-enhanced Li-ion batteries for the energy storage, industrial, and defense markets. NanoXplore holds over 100 patents and patent applications protecting its intellectual property, products, and process knowledge, and is one of a limited number of companies authorized to produce and sell graphene at commercial scale in Canada, the United States, the United Kingdom, and the European Union, holding Environment and Climate Change Canada (ECCC) and Health Canada certification, U.S. EPA certification, and UK and EU REACH registrations.

Please visit www.nanoxplore.ca  

For further information, please contact:  

Rocco Marinaccio
President and Chief Executive Officer
Rocco.Marinaccio@nanoxplore.ca

MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2026 after the close of trading on Monday, November 2. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire’s Q3 2026 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Inspire’s Q3 2026 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

Following the call, a replay will be available on the Company’s Investor Relations website approximately two hours after the event and archived on the site for two weeks.

About Inspire Medical Systems

Inspire Medical Systems is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor Contact

Brian Johnston or Louisa Smith

Gilmartin Group, LLC

IR@inspiresleep.com

BOSTON, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED (“ARCHIMED”), a leading investment firm focused exclusively on healthcare industries.

Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools, said, “ARCHIMED brings deep healthcare and life sciences expertise, a strong understanding of the market and the resources to support the business’ next chapter. This is a strong outcome for our employees and our customers, and we believe the business will continue to grow and innovate under new ownership. This transaction marks another important step in the strategic actions we laid out for Standard BioTools and our shareholders.”

The transaction is expected to close in approximately 30 days, subject to customary closing conditions. Until closing, the Microfluidics business will continue to operate as part of Standard BioTools.

About Standard BioTools Inc.

Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. The Company’s established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/notices. Trademarks: standardbio.com/legal/terms-and-conditions/.

Patent and License Information: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2026 Standard BioTools Inc. All rights reserved.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the disposition of the Microfluidics business and the expected outcome, timing and benefits of such disposition. The words “strong,” “continue,” “grow,” “innovate,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks, uncertainties, and assumptions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: (i) the risk that the sale of the Microfluidics business may not be completed in a timely manner or at all; (ii) the possibility that any or all of the various conditions to the consummation of the sale of the Microfluidics business may not be satisfied or waived; (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement relating to the sale of the Microfluidics business, including in circumstances that would require Standard BioTools to pay a termination fee or other expenses; and (iv) the possibility that competing offers or acquisition proposals will be made with respect to the Microfluidics business.

For information regarding other related risks, see the “Risk Factors” section of Standard BioTools’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2026, Standard BioTools’ most recent Quarterly Report on Form 10-Q and Standard BioTools’ other filings with the SEC. Should any of these risks or uncertainties materialize, actual results could differ materially from expectations. These forward-looking statements speak only as of the date hereof. Standard BioTools does not assume any obligation to, and does not currently intend to, update any such forward-looking statements except as may be required by law.

Additional Information and Where to Find It

This press release may be deemed to be solicitation material in respect of the proposed transactions involving Standard BioTools and Treeline Biosciences, Inc. (“Treeline”) and/or Standard BioTools’ sale of its Mass Cytometry business to Element Biosystems, LLC (“Element”). In connection with the Treeline transaction and related stockholder vote, Standard BioTools has filed with the SEC a registration statement on Form S-4 on July 20, 2026 that included a preliminary proxy statement and a preliminary prospectus of Standard BioTools, and that may be amended or supplemented from time to time. This communication is not a substitute for the preliminary proxy statement/preliminary prospectus or any other document that Standard BioTools may file with the SEC or send to its stockholders in connection with the proposed transactions. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. Any definitive proxy statement/prospectus (if and when available) will be mailed to stockholders of Standard BioTools.

INVESTORS AND STOCKHOLDERS OF STANDARD BIOTOOLS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS, SUPPLEMENTS AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN) AND OTHER RELEVANT MATERIALS FILED OR TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE MAKING ANY VOTING DECISION WITH RESPECT TO THE PROPOSED TRANSACTIONS BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT STANDARD BIOTOOLS, TREELINE, ELEMENT AND THE PROPOSED TRANSACTIONS. Copies of the materials filed or to be filed by Standard BioTools with the SEC may be obtained free of charge on Standard BioTools’ Investor Relations website at https://investors.standardbio.com or by contacting Standard BioTools’ Investor Relations department at ir@standardbio.com. In addition, all of those materials will be available at no charge on the SEC’s website at www.sec.gov.

Participants in the Solicitation

Standard BioTools, Treeline and certain of their respective directors, executive officers, other members of management and employees may be deemed to be participants in the solicitation of proxies of Standard BioTools stockholders in connection with the proposed transactions under SEC rules. Investors and stockholders may obtain more detailed information regarding the names, affiliations and interests of Standard BioTools’ executive officers and directors who may, under SEC rules, be deemed participants in the solicitation by reading Standard BioTools’ proxy statement for its 2026 annual meeting of stockholders (including under the headings “Management and Corporate Governance,” “Executive Officer and Director Compensation,” “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters,” “Executive Compensation” and “Certain Relationships and Related Transactions, and Director Independence”), its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and Standard BioTools’ other filings with the SEC. Information regarding Treeline’s directors and executive officers who may be deemed participants in the solicitation is contained in the registration statement on Form S-4 filed by Standard BioTools. These documents are or will be available free of charge at the SEC’s website at www.sec.gov or by going to Standard BioTools’ Investor Relations website at http://investors.standardbio.com or contacting Standard BioTools’ Investor Relations department at ir@standardbio.com.

Contacts:

Standard BioTools:

IR:
ir@standardbio.com

Media:
Dan Moore / Nick Lamplough / Tali Epstein
Collected Strategies
LAB-CS@collectedstrategies.com